DexCom (NASDAQ:DXCM) Price Target Raised to $95.00 at Mizuho

DexCom (NASDAQ:DXCM) had its price target upped by Mizuho from $90.00 to $95.00 in a research note released on Friday morning,Benzinga reports. Mizuho currently has an outperform rating on the medical device company’s stock.

Several other analysts also recently commented on DXCM. Citigroup reissued a “buy” rating and issued a $88.00 target price (up from $84.00) on shares of DexCom in a research report on Friday. Canaccord Genuity Group set a $82.00 price objective on shares of DexCom and gave the stock a “buy” rating in a report on Monday, May 18th. Piper Sandler reissued an “overweight” rating and set a $95.00 target price (up from $88.00) on shares of DexCom in a research report on Friday. UBS Group set a $96.00 target price on DexCom and gave the company a “buy” rating in a report on Tuesday. Finally, William Blair raised DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $88.12.

DexCom Stock Up 12.0%

Shares of DexCom stock opened at $83.45 on Friday. The firm has a market cap of $32.20 billion, a price-to-earnings ratio of 32.98, a P/E/G ratio of 1.23 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. DexCom has a 52-week low of $54.11 and a 52-week high of $87.00. The stock has a 50-day simple moving average of $73.14 and a 200-day simple moving average of $69.20.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a return on equity of 35.34% and a net margin of 20.12%.The firm’s revenue was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.48 earnings per share. On average, equities research analysts expect that DexCom will post 2.57 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In related news, insider Kevin R. Sayer sold 26,759 shares of the stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the completion of the sale, the insider owned 382,482 shares in the company, valued at $27,538,704. This represents a 6.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,912 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $73.00, for a total value of $358,576.00. Following the completion of the sale, the executive vice president directly owned 100,361 shares in the company, valued at $7,326,353. This trade represents a 4.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 98,506 shares of company stock worth $7,205,258 in the last ninety days. 0.28% of the stock is owned by insiders.

Institutional Investors Weigh In On DexCom

Several hedge funds have recently modified their holdings of DXCM. Reflection Asset Management bought a new position in DexCom during the fourth quarter worth $25,000. Ascentis Independent Advisors acquired a new position in DexCom during the 1st quarter valued at $25,000. MCF Advisors LLC bought a new stake in DexCom in the 4th quarter valued at $32,000. Wellington Grp LLC boosted its holdings in DexCom by 778.7% in the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 475 shares during the period. Finally, DV Equities LLC bought a new stake in DexCom in the 4th quarter valued at $36,000. 97.75% of the stock is owned by institutional investors.

Key Stories Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly beat and higher outlook: DexCom reported adjusted earnings of $0.70 per share versus the $0.61 consensus, while revenue rose 13.1% year over year to $1.31 billion, exceeding estimates of $1.29 billion. Management raised its 2026 revenue outlook to approximately $5.18 billion-$5.25 billion, supported by strong global demand and broader product access. Reuters article
• Positive Sentiment: Product and market expansion: Growth is being supported by the G7 15 Day continuous glucose monitor, with DexCom targeting nearly 50% U.S. conversion by year-end, as well as expanded access and continued international growth. Margin improvement also contributed to a more constructive 2026 earnings narrative. Seeking Alpha article
• Positive Sentiment: Broad analyst support: Mizuho raised its price target to $95, Royal Bank of Canada and Wells Fargo lifted targets to $90, and UBS reaffirmed a Buy rating with a $96 target. Benchmark also reaffirmed Buy, although its $82 target is below the referenced trading level. Benzinga analyst updates
• Neutral Sentiment: Mixed valuation signals: JPMorgan raised its target substantially to $82 but retained a Neutral rating, indicating that some analysts view much of the improved outlook as already reflected in the stock.
• Negative Sentiment: Insider selling: Quiver Quantitative data shows 14 insider sales and no purchases during the past six months. This is a potential cautionary signal, although it has not outweighed the earnings-driven optimism. Quiver Quantitative analysis

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.